Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that generic erosion of premium-priced branded agents will offset sales of new agents and will cause the acute coronary syndrome market for drugs in the hospital setting to decrease from $800 million in 2008 to $729 million in 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.
The new Pharmacor report entitled Acute Coronary Syndrome finds that, through 2018, the patent expiries of Merck/GlaxoSmithKline's Integrilin, Merck/Medicure's Aggrastat and Sanofi-Aventis's Lovenox/Clexane will be the key factors constraining the market. Among these agents, generic erosion of Integrilin will be the most significant as its sales will decrease by approximately $100 million from 2008 to 2018. However, Merck will recoup some of these losses with the 2011 launch of its adenosine agonist, Acadesine, which is expected to be the first agent to receive regulatory approval for reperfusion injury.
The most advanced agent in development, AstraZeneca's Brilinta, is the most likely emerging therapy to change medical practice for acute coronary syndrome. In a Phase III clinical trial, Brilinta significantly reduced the risk of mortality compared with clopidogrel (Bristol-Myers Squibb/Sanofi-Aventis's Plavix/Iscover, generics), which has been a mainstay in the treatment of acute coronary syndrome. Following its launch next year, Brilinta sales in 2010 are forecasted to reach $21 million in the acute treatment setting, although it has blockbuster potential for treatment of post-myocardial infarction.